<DOC>
	<DOCNO>NCT01742078</DOCNO>
	<brief_summary>The purpose study determine single dose LY2541546 side effect body determine long much LY2541546 stay bloodstream body .</brief_summary>
	<brief_title>A Study LY2541546 Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<criteria>Healthy postmenopausal female , determine medical history physical examination Body mass index ( BMI ) screen 19.0 32.0 kilogram per square meter ( kg/m^2 ) , inclusive Acceptable Clinical laboratory test result , blood pressure heart rate Have give write informed consent Additional Inclusion Criterion Participants Open Label Groups : Are currently take recently discontinue ( 3 month prior study randomization ) alendronate take alendronate least 12 last 18 month Within 30 day initial dose study drug , receive treatment drug receive regulatory approval indication Known allergy LY2541546 , constituent , related compound Persons previously participate study History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder History high risk adverse outcome bleeding , example , transient ischemic attack , cerebrovascular attack , ulcer disease Paget 's disease , parathyroid disease , thyroid disease Fracture long bone within 12 week screen Regular use know drug abuse and/or positive finding urinary drug screen Evidence human immunodeficiency virus ( HIV ) , hepatitis C , hepatitis B and/or positive antiHIV antibody , hepatitis C antibody , hepatitis B surface antigen Current use therapy osteoporosis use hormone replacement therapy ( HRT ) within previous 12 month Blood donation within last month Participants average weekly alcohol intake exceed 14 unit per week Cigarette consumption 10 cigarette per day , unable unwilling refrain nicotine Clinical Research Unit ( CRU ) confinement Additional Exclusion Criterion Participants Double Blind Groups Only Have receive bisphosphonates previous 24 month . Additional Exclusion Criterion Participants Open Label Groups Have receive intravenous bisphosphonates within previous 18 month</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Postmenopausal female</keyword>
	<keyword>Volunteers</keyword>
</DOC>